SET and Familial prostate cancer: It was reported that the suppression of SMYD3 could attenuated malignant phenotype of prostate cancer either by deleting the SET function domain or silencing SMYD3, indicating the function of SMYD3 on tumor growth might associated with histone methyltransferase activity.